Cargando…

Vitiligo at Injection Site of PEG-IFN-α 2a in Two Patients with Chronic Hepatitis C: Case Report and Literature Review

A 72-year-old female and a 57-year-old male with chronic hepatitis C were treated with a combination therapy of pegylated interferon (PEG-IFN)-α 2a (180 μg s.c. once a week) and ribavirin (1,000 mg orally daily). This resulted in the destruction of melanocytes at the injection site in both patients....

Descripción completa

Detalles Bibliográficos
Autores principales: Arya, V., Bansal, M., Girard, L., Arya, S., Valluri, A.
Formato: Texto
Lenguaje:English
Publicado: S. Karger AG 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2978742/
https://www.ncbi.nlm.nih.gov/pubmed/21076689
http://dx.doi.org/10.1159/000320207
_version_ 1782191294738595840
author Arya, V.
Bansal, M.
Girard, L.
Arya, S.
Valluri, A.
author_facet Arya, V.
Bansal, M.
Girard, L.
Arya, S.
Valluri, A.
author_sort Arya, V.
collection PubMed
description A 72-year-old female and a 57-year-old male with chronic hepatitis C were treated with a combination therapy of pegylated interferon (PEG-IFN)-α 2a (180 μg s.c. once a week) and ribavirin (1,000 mg orally daily). This resulted in the destruction of melanocytes at the injection site in both patients. In the male patient, the depigmentation progressed to the surrounding skin area. The dermatologist concurred with vitiligo as the diagnosis in both patients. Injection and surrounding site vitiligo associated with PEG-IFN-α 2b treatment for hepatitis C was noticed in previous case studies. For the first time, the case reports below highlight the same immunological adverse event secondary to PEG IFN-α 2a/ribavirin combination therapy and explain, in part, the complex interaction between host immune response and viral genotype. In addition, we systematically review drug-induced vitiligo and autoimmune diseases associated with the depigmentation disorder.
format Text
id pubmed-2978742
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-29787422010-11-12 Vitiligo at Injection Site of PEG-IFN-α 2a in Two Patients with Chronic Hepatitis C: Case Report and Literature Review Arya, V. Bansal, M. Girard, L. Arya, S. Valluri, A. Case Rep Dermatol Published: August 2010 A 72-year-old female and a 57-year-old male with chronic hepatitis C were treated with a combination therapy of pegylated interferon (PEG-IFN)-α 2a (180 μg s.c. once a week) and ribavirin (1,000 mg orally daily). This resulted in the destruction of melanocytes at the injection site in both patients. In the male patient, the depigmentation progressed to the surrounding skin area. The dermatologist concurred with vitiligo as the diagnosis in both patients. Injection and surrounding site vitiligo associated with PEG-IFN-α 2b treatment for hepatitis C was noticed in previous case studies. For the first time, the case reports below highlight the same immunological adverse event secondary to PEG IFN-α 2a/ribavirin combination therapy and explain, in part, the complex interaction between host immune response and viral genotype. In addition, we systematically review drug-induced vitiligo and autoimmune diseases associated with the depigmentation disorder. S. Karger AG 2010-08-27 /pmc/articles/PMC2978742/ /pubmed/21076689 http://dx.doi.org/10.1159/000320207 Text en Copyright © 2010 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial-No-Derivative-Works License (http://creativecommons.org/licenses/by-nc-nd/3.0/). Users may download, print and share this work on the Internet for noncommercial purposes only, provided the original work is properly cited, and a link to the original work on http://www.karger.com and the terms of this license are included in any shared versions.
spellingShingle Published: August 2010
Arya, V.
Bansal, M.
Girard, L.
Arya, S.
Valluri, A.
Vitiligo at Injection Site of PEG-IFN-α 2a in Two Patients with Chronic Hepatitis C: Case Report and Literature Review
title Vitiligo at Injection Site of PEG-IFN-α 2a in Two Patients with Chronic Hepatitis C: Case Report and Literature Review
title_full Vitiligo at Injection Site of PEG-IFN-α 2a in Two Patients with Chronic Hepatitis C: Case Report and Literature Review
title_fullStr Vitiligo at Injection Site of PEG-IFN-α 2a in Two Patients with Chronic Hepatitis C: Case Report and Literature Review
title_full_unstemmed Vitiligo at Injection Site of PEG-IFN-α 2a in Two Patients with Chronic Hepatitis C: Case Report and Literature Review
title_short Vitiligo at Injection Site of PEG-IFN-α 2a in Two Patients with Chronic Hepatitis C: Case Report and Literature Review
title_sort vitiligo at injection site of peg-ifn-α 2a in two patients with chronic hepatitis c: case report and literature review
topic Published: August 2010
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2978742/
https://www.ncbi.nlm.nih.gov/pubmed/21076689
http://dx.doi.org/10.1159/000320207
work_keys_str_mv AT aryav vitiligoatinjectionsiteofpegifna2aintwopatientswithchronichepatitisccasereportandliteraturereview
AT bansalm vitiligoatinjectionsiteofpegifna2aintwopatientswithchronichepatitisccasereportandliteraturereview
AT girardl vitiligoatinjectionsiteofpegifna2aintwopatientswithchronichepatitisccasereportandliteraturereview
AT aryas vitiligoatinjectionsiteofpegifna2aintwopatientswithchronichepatitisccasereportandliteraturereview
AT valluria vitiligoatinjectionsiteofpegifna2aintwopatientswithchronichepatitisccasereportandliteraturereview